Evidence map›Paper›PMID 17333036›Full record

ArticleDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2007

[Lymphadenectomy with tumors of the lower gastrointestinal tract].

W Hohenberger, S Merkel, K Weber

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Complete mesocolic excision for colon cancer: is it worth it?Journal of gastrointestinal oncology · 2019
    Review
  5. Article
  6. LaparoscopicWorld journal of gastrointestinal oncology · 2017
    Article
  7. Article
  8. Laparoscopic complete mesocolic excision: West meets East.World journal of gastroenterology · 2014
    Review
  9. Observational
  10. Is there a disadvantage to radical lymph node dissection in colon cancer?International journal of colorectal disease · 2013
    Article
  11. Article
  12. [Lymph node dissection for carcinomas of the lower gastrointestinal tract. What is evidence-based?].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2011
    Review
  13. Article
  14. [Tumors of the lower gastrointestinal tract : Indication and extent of lymph node dissection].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2010
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

W HohenbergerChirurgische Klinik, Universität Erlangen-Nürnberg, Krankenhausstrasse 12, 91054 Erlangen. sekretariat@chir.imed.uni-erlangen.de
S Merkel
K Weber

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For advanced adenocarcinomas, which are the most frequent tumours of the lower GI tract, the concept of radical lymphnode dissection is well accepted. The quality of lymphadenectomy for these malignancies has a strong effect on cancer-related survival. Based upon a strict quality control program with outcome evaluated according to internal results, the technique and extent of lymph node dissection have been continuously developed over the last three decades. These are described in detail, including instructive pictures to clarify the surgical steps needed. Apart from multivisceral resection in far advanced cases, which still have a chance of cure if adequate guidelines are followed, two additional steps in the so-called radical surgical treatment of these tumours are prerequisites for cure. The first is complete mobilisation of the intestine involving complete mesocolic excision with complete retention of the visceral fascia and covering potential lymph node metastases and extranodal spread on the intestinal side. The second step is the central tying of the tumor's supplying vessels. Following these rules and with no adjuvant systemic treatment, 5-year survival figures of 80% can be reached, even for UICC stage III disease.

Indexed as

AdenocarcinomaAnus NeoplasmsColorectal NeoplasmsGastrointestinal Stromal TumorsHumansIntestinal NeoplasmsIntestinesLymphatic MetastasisLymph Node ExcisionLymph NodesLymphomaNeoplasm StagingNeuroendocrine TumorsPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.